BOSTON--(BUSINESS WIRE)--Lundbeck announced today that it will present 12 abstracts at the 2017 American Academy of Neurology (AAN) Annual Meeting in Boston, Massachusetts, on April 22-28, 2017. Two of these abstracts have been accepted for oral platform presentation at the meeting.
“Lundbeck has a proud legacy in brain disorder research and drug development that spans more than 70 years. Despite the complexities associated with CNS research, we continue to persevere because we know that the need is great,” said Krai-rith Chatamra, PhD, Medical Affairs Head of Neurology US. “The data we are presenting at AAN this year are a testament to our endless dedication to the people who are living with challenging brain disorders – including those with rare conditions that often go under-recognized.”
Lundbeck data to be presented at AAN include the following highlights:
Neurogenic Orthostatic Hypotension (nOH)
Impact of Neurogenic Orthostatic Hypotension (nOH) on Healthcare Costs in Patients with Parkinson’s Disease (Oral 003)
- Location/Date: Oral Platform Presentation Session S11 – Autonomic Disorders: Synucleinopathies, Monday, April 24 at ~1:24 p.m.
Analysis of Neurogenic Orthostatic Hypotension (nOH) treatment in Patients with Parkinson’s Disease (Poster 321)
- Location/Date: Poster Presentation – Poster Session 5, Thursday, April 27, 8:30 AM - 7:00 PM
Anti-Epileptic Drug Seven-Year Registry Data (Oral 004)
- Location/Date: Oral Platform Presentation Session S55 – Epilepsy & Clinical Neurophysiology (EEG) III, Friday, April 28 at ~4:06 pm
Development and Validation of the Refractory Epilepsy Screening Tool for Lennox-Gastaut Syndrome (REST-LGS): Improving Detection of LGS (Poster 240)
- Location/Date: Poster Presentation, Poster Session 4, Wednesday, April 26, 8:30AM - 7:00 PM
Follow @LundbeckUS on Twitter throughout the meeting for updates, reminders and news regarding data presentations, as well as other professional and patient-focused initiatives.
Lundbeck is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of research focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.
An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders — we call this Progress in Mind.
Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6 billion in 2016 (EUR 2.1 billion; USD 2.2 billion).
In the U.S., Lundbeck employs nearly 1,000 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck U.S. actively engages in hundreds of initiatives each year that support our patient communities. For additional information, we encourage you to visit our corporate site at www.lundbeckus.com and connect with us on Twitter at @LundbeckUS.